| Previous Close | 70.65 |
| Open | 70.97 |
| Bid | 71.95 x 300 |
| Ask | 72.10 x 200 |
| Day's Range | 70.83 - 72.09 |
| 52 Week Range | 63.76 - 88.85 |
| Volume | 10,606,185 |
| Avg. Volume | 8,547,356 |
| Market Cap | 93.98B |
| Beta | 0.97 |
| PE Ratio (TTM) | 7.60 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.92%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- Investopedia•10 hours ago
Why Gilead Is Still a Value Trap
Gilead Sciences remains a value trap because it's still not doing anything with its cash.
SmarterAnalyst•yesterdayHealthcare Guru Samuel Isaly Plays Two Key Biotech Stocks: Synergy Pharmaceuticals Inc (SGPY), Gilead Sciences, Inc. (GILD)
Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Gilead Sciences Inc (NASDAQ:GILD). Isaly is the managing partner of OrbiMed, a global management firm that has assets under management of over $13 billion. Isaly is closely tracked by investors due to his exceptional track record: at the beginning of 2016, Barron’s said he was the only US mutual fund manager to beat the S&P 500 for an incredible 25 straight years.
- Zacks•2 days ago
Gilead's (GILD) HCV Drug Application Accepted in the EU
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
